http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Sep 2025 07:32:27 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html <p>Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.</p><p>Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.</p><p>The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.</p><p>“The lack of momentum http://www.streetinsider.com/Investing/M.+Stanley+cuts+Novo+Nordisk+to+Underweight+on+%E2%80%99tough+path+ahead%E2%80%99%2C+shares+slip/25388072.html Mon, 29 Sep 2025 07:32:27 -0500 LLY NOVG NOVN NOVNEE NVO NVON NVOP NVS NVSEF NVSN SANF SASY SNY SNYN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/General+News/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html <p>Investing.com -- Monte Rosa Therapeutics (NASDAQ: GLUE) shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degraders (MGDs) for immune-mediated diseases.</p><p dir="ltr">The Boston-based firm said Novartis will receive an exclusive license to one undisclosed discovery target, along with options to license two additional preclinical immunology programs. </p><p dir="ltr">Monte Rosa will receive an upfront payment of $120 million and is eligible for option maintenance fees, development and regulatory milestones, and tiered royalties on global net sales. The total deal value could reach http://www.streetinsider.com/Investing/Monte+Rosa+surges+premarket+on+Novartis+collaboration+deal/25332686.html Mon, 15 Sep 2025 08:16:05 -0500 GLUE NOVN NOVNEE NVS NVSEF NVSN